MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
0.3400
-0.0200
-5.56%
After Hours: 0.3456 +0.0056 +1.65% 18:14 05/09 EDT
OPEN
0.3573
PREV CLOSE
0.3600
HIGH
0.3596
LOW
0.3350
VOLUME
633.70K
TURNOVER
--
52 WEEK HIGH
44.03
52 WEEK LOW
0.3350
MARKET CAP
2.13M
P/E (TTM)
-0.0001
1D
5D
1M
3M
1Y
5Y
1D
APTEVO THERAPEUTICS : IN PRECLINICAL STUDIES APVO711 DEMONSTRATES DUAL ANTI-CANCER FUNCTIONALITY WITH BROAD SOLID TUMOR POTENTIAL & DEVELOPABILITY
Reuters · 1d ago
Aptevo Therapeutics provides program update for APVO711
TipRanks · 1d ago
Aptevo Therapeutics Inc <APVO.OQ> expected to post a loss of $4.21 a share - Earnings Preview
Reuters · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at APVO last week (0428-0502)?
Weekly Report · 4d ago
Aptevo Therapeutics files to sell 3.53M shares of common stock for holders
TipRanks · 05/02 21:05
Weekly Report: what happened at APVO last week (0421-0425)?
Weekly Report · 04/28 10:18
Biotech Alert: Searches spiking for these stocks today
TipRanks · 04/23 17:45
More
About APVO
More
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Recently
Symbol
Price
%Change

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.